Augmentin Indications/Uses

AUGMENTIN should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Susceptibility to AUGMENTIN will vary with geography and time (see Pharmacology: Pharmacodynamics under Actions for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
Tablet: AUGMENTIN is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics.
AUGMENTIN oral presentations for twice daily dosing, are indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis, lobar and bronchopneumonia.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. boils, abscesses, cellulitis, wound infections.
Bone and joint infections e.g. osteomyelitis.
Dental infections e.g. dentoalveolar abscess.
Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
Oral suspension: AUGMENTIN suspension (228 mg/5 mL and 457 mg/5 mL), for twice daily oral dosing, is indicated for short-term treatment of bacterial infections at the following sites when amoxicillin-resistant beta-lactamase producing strains are suspected as the cause. In other situations, amoxicillin alone should be considered.
Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia.
Urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. cellulitis, animal bites.
Dental infections e.g. severe dental abscess with spreading cellulitis.
Mixed infections caused by amoxicillin-susceptible organisms in conjunction with AUGMENTIN susceptible beta-lactamase-producing organisms may be treated with AUGMENTIN suspension 228 mg/5 mL and 457 mg/5 mL. These infections should not require the addition of another antibiotic-resistant to beta-lactamases.
Injection: AUGMENTIN is indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis, lobar and bronchopneumonia.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. boils, abscesses, cellulitis, wound infections.
Bone and joint infections e.g. osteomyelitis.
Other infections e.g. intra-abdominal sepsis.
AUGMENTIN intravenous is also indicated for prophylaxis against infection which may be associated with major surgical procedures such as gastrointestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract.
Infections caused by amoxicillin-susceptible organisms are amenable to AUGMENTIN treatment due to its amoxicillin content. Mixed infections caused by amoxicillin-susceptible organisms in conjunction with AUGMENTIN-susceptible β-lactamase producing organisms may therefore be treated with AUGMENTIN.